A 3-year-follow-up study on the prognosis of ‘two-route chemotherapy’ on liver cancer patients with portal vein tumor thrombus
10.3760/cma.j.issn.0254-6450.2012.11.019
- VernacularTitle:双途径化疗对合并门静脉癌栓肝癌患者预后的影响(3年随访报告)
- Author:
Huan-Hu ZHANG
1
;
Sheng-Bo SUN
;
Chuan-Ji HAN
;
Shao-Wei SUN
Author Information
1. 264200,山东省威海市立医院
- Keywords:
Hepatic cell cancer;
Portal vein tumor thrombus;
Transcatheter arterial chemoembolization;
Portal vein chemotherapy
- From:Chinese Journal of Epidemiology
2012;33(11):1181-1183
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the achievements and safety of Transcatheter arterial chemoembolization (TACE) associated Portal Vein Chemo-therapy (PVC) per-drug delivery system (DDS) program in preventing the recurrence of hepatic cell cancer (HCC) and Portal Vein Tumor Thrombus (PVTT).Methods 97 cases with HCC and PVTT were treated from Januay 2009 to January 2011.Patients with tumor or tumor thrombus were resected on all the cases and randomly divided into 3 groups.TACE,PVC per-DDS TACE and PVC per-DDS were given to group A,group B,and group C,respectively.Patients in the 3 groups were followed and compared on the Disease Free Survivals (DFS) and the accumulative survival rates,at 6 months,1 year and 2 years after the operation.Results After the surgery was completed in June,the 1-year,2-year,3-year survival rates and cummulative survival rate in group C was higher than in group A or group.Significant differences did no appeare in June but did show in 1 year after the surgery (P＞0.05) as well as in both 2 and 3 years,after the surgery (P＜0.01).Conclusion Patients with HCC and PVTT,the TACE chemotherapy in association with PVC per-DDS could increase both the DFSs and accumulative survival rates,when compared to the either single TACE or PVC per-DDS,after the tumor or tumor thrombus were resected.
